Roche Holding AG
RHHBYDrugs in Pipeline
497
Phase 3 Programs
270
Upcoming Catalysts
54
Next Catalyst
This month
Market Overview
Stock performance and key metrics
58 upcoming, 10 past
Ocrelizumab Test Formulation Phase 2 Est. Readout
Estimated primary completion for Ocrelizumab Test Formulation trial (NCT07074886) in Multiple Sclerosis. Topline data typically follows completion by weeks to months.
Source57 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How RHHBY's past catalysts played out
RO7239361
Duchenne Muscular Dystrophy
RO7204239
Obesity
trastuzumab (Herceptin®)
Breast Cancer
mycophenolate mofetil [CellCept]
Myasthenia Gravis Generalised
Lenvatinib
Unresectable Hepatocellular Carcinoma
Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
Pirfenidone
Lung Diseases, Interstitial
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Carcinoma, Non-Squamous Non-Small Cell Lung
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Early Breast Cancer
Trastuzumab IV
HER2-positive Early Breast Cancer
Other Combination Anti-Cancer Therapies
Solid Tumors
Valganciclovir
Cytomegalovirus Infections
Filgrastim
Triple-negative Breast Cancer
methoxy polyethylene glycol-epoetin beta [Mircera]
Anemia
Herceptin
Breast Cancer
Trastuzumab Emtansine
Breast Cancer
Fenebrutinib
Relapsing Multiple Sclerosis
Glofitamab
Diffuse Large B-cell Lymphoma
Alectinib
Non-Small Cell Lung Cancer
capecitabine [Xeloda]
Colorectal Cancer
Peginterferon alfa-2a
Carcinoma, Hepatocellular
Cladribine
Lymphocytic Leukemia, Chronic
ibandronate [Bonviva/Boniva]
Post-Menopausal Osteopenia
Trontinemab
Alzheimers Disease
aleglitazar
Diabetes Mellitus Type 2
Alectnib
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Non-Small Cell Lung Cancer
Inavolisib
Breast Cancer
Leucovorin (LV)
Colorectal Cancer
CHOP
Lymphoma, Large B-Cell, Diffuse
rituximab [MabThera]
Rheumatoid Arthritis
RO4917838
Schizophrenia
Baseline Treatment
Neuromyelitis Optica (NMO)
Acetaminophen/Paracetamol
Systemic Lupus Erythematosus
Phesgo
Locally Advanced or Metastatic Breast Cancer
Fludarabine Phosphate
Chronic Lymphocytic Leukemia
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Anemia
Ortho-Novum® 1/35
Rheumatoid Arthritis
PEGASYS
Hepatitis C, Chronic
RO7771950
HER2-positive Breast Cancer
orlistat [Xenical]
Obesity
aleglitazar+metformin
Diabetes Mellitus Type 2
dalcetrapib
Coronary Heart Disease
Tiragolumab and Atezolizumab
Cancer
Cobimetinib
Melanoma
DMARDs
Rheumatoid Arthritis
MabThera/Rituxan
Rheumatoid Arthritis
RO7234292
Huntingtons Disease
Onartuzumab [MetMAb]
Non-Small Cell Lung Cancer
epoetin beta [NeoRecormon]
Anemia
Crovalimab
Atypical Hemolytic Uremic Syndrome
Entecavir
Pediatric Immuno-Tolerant Chronic Hepatitis B
Mosunetuzumab
Non-Hodgkin Lymphoma
Prasinezumab
Parkinsons Disease
Dalcetrapib (RO4607381)
Coronary Heart Disease
FEC Chemotherapy
Breast Cancer
Darbepoetin alfa
Anemia
Interferon beta-1a
Relapsing Multiple Sclerosis
Evidence-based medical care for Acute Coronary Syndrome
Coronary Heart Disease
Tiragolumab
Small Cell Lung Cancer
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Anemia
methylprednisolone
Rheumatoid Arthritis
Vamikibart
Diabetic Macular Edema
Factor VIII (FVIII)
Hemophilia A
Pralsetinib
RET-fusion Non Small Cell Lung Cancer
Anti-VEGF Therapy
Neovascular Age-related Macular Degeneration
epoetin alfa or beta
Anemia
Zidovudine
HIV Infections
Remdesivir
COVID-19 Pneumonia
Polatuzumab Vedotin
Non-Hodgkin's Lymphoma
r-HuEPO
Anemia
Fingolimod
Relapsing-Remitting Multiple Sclerosis
Teriflunomide
Relapsing Multiple Sclerosis
Sefaxersen (RO7434656)
Primary IgA Nephropathy
tocilizumab [RoActemra]
Rheumatoid Arthritis
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Rheumatoid Arthritis
Tocilizumab (TCZ)
Rheumatoid Arthritis
Valganciclovir CMV Prophylaxis
Cytomegalovirus Infections
Neo-adjuvant chemotherapy
Breast Cancer
Enfuvirtide
HIV Infections
Pertuzumab
Breast Cancer
Taxane-based chemotherapy
Breast Cancer
Cyclosporine
Renal Transplantation
23-PPV
Multiple Sclerosis, Relapsing-Remitting
FAP IL2V
Cancer
Alimta or Taxotere
Non-Small Cell Lung Cancer
Oxaliplatin 130 mg/m^2
Colorectal Cancer
Non-steroidal anti-inflammatory drugs (NSAIDs)
Juvenile Idiopathic Arthritis
chlorambucil
Lymphocytic Leukemia, Chronic
5-Fluoruracil
Gastric Cancer
Giredestrant
Endometrial Cancer
Oseltamivir IV
Influenza
Interferon alfa 2a [Roferon]
Renal Cell Cancer
Disease-modifying anti-rheumatic drugs
Rheumatoid Arthritis
Becavizumab
Hepatocellular Carcinoma
Azathioprine
Rheumatoid Arthritis
Crizotinib
Neoplasms
Bitopertin
Beta-Thalassemia
Pegylated Interferon Alfa-2a
Chronic Myelogenous Leukemia
Divarasib
Non-Small Cell Lung Cancer
Rituximab SC
Non-Hodgkin's Lymphoma
saquinavir [Invirase]
HIV Infections
Optimized background antiretroviral regimen (OB)
HIV Infections
Permitted DMARDs
Rheumatoid Arthritis
exenatide
Diabetes Mellitus Type 2
Ocrelizumab IV
Relapsing Multiple Sclerosis
bitopertin [RO4917838] level 1
Schizophrenia
MTX
Rheumatoid Arthritis
Antipsychotics
Schizophrenia
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Hepatitis B, Chronic
Prednisone/Prednisolone
Metastatic Prostate Cancer
Recombinant Hepatitis B Virus Vaccine
Hepatitis B
rFVIIa
Hemophilia A
Taxotere
Breast Cancer
Fluoropyrimidine-based Chemotherapy
Colorectal Cancer
CDK4/6i
Breast Cancer
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Diabetic Retinopathy
CMF
Breast Cancer
Stavudine
HIV Infections
Ganciclovir
Cytomegalovirus Retinitis
tocilizumab SC
Rheumatoid Arthritis
Lamivudine
HIV Infections
PDS Implant with Ranibizumab 100 mg/mL
Neovascular Age-Related Macular Degeneration
Erlotinib
Non-Squamous Non-Small Cell Lung Cancer
satralizumab
Neuromyelitis Optica Spectrum Disorder
MMF
Lupus Nephritis
interferon-a-2a
Lymphoma
Baloxavir Marboxil
Influenza
TRO19622
Amyotrophic Lateral Sclerosis
XELOX
Colorectal Cancer
Standard adjuvant chemotherapy
Breast Cancer
DMARD
Rheumatoid Arthritis
Mycophenolate Mofetil 2 g/Day
Pemphigus Vulgaris (PV)
Lebrikizumab
Asthma
Faricimab
Wet Macular Degeneration
Pegylated-interferon Alfa-2a
Hepatitis C, Chronic
Standard chemotherapy
Breast Cancer
von Willebrand Factor (VWF) Concentrates
Von Willebrand Disease, Type 3
Oral Corticosteroids
Rheumatoid Arthritis
valganciclovir [Valcyte]
Cytomegalovirus Infections
bevacizumab, erlotinib
Colorectal Cancer
Acetaminophen/ Paracetamol
Childhood Idiopathic Nephrotic Syndrome
Corticosteroids
Breast Cancer
Antihistamine
Multiple Sclerosis
epoetin
Anemia
Human Coagulation Factor VIII
Hemophilia A
fusidic acid [Verutex]
Non-Small Cell Lung Cancer
Rituximab IV
Lymphoma, Large B-Cell, Diffuse
Risdiplam
Muscular Atrophy, Spinal
Ocrelizumab
Multiple Sclerosis
Pegylated Interferon (PEG-IFN) alfa-2a
Hepatitis D, Chronic
oseltamivir
Influenza, Human
Gemcitabine (Chemotherapy)
Ovarian Cancer
Second-Line Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Zalcitabine
HIV Infections
Efavirenz
HIV Infections
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Cevostamab
Multiple Myeloma
Etrozulimab
Ulcerative Colitis
Vinflunine
Bladder Cancer
Neoral
Kidney Transplantation
Gantenerumab
Alzheimer's Disease
PDS Implant filled with 100 mg/mL Ranibizumab
Neovascular Age-Related Macular Degeneration
anti-IL-2R
Kidney Transplantation
Endocrine Therapy of Physician's Choice
Early Breast Cancer
Delavirdine mesylate
HIV Infections
adefovir dipivoxil
Hepatitis B, Chronic
Chemotherapy (Induction Period)
Non-Hodgkin's Lymphoma
tenofovir
Hepatitis D, Chronic
RO0503821 (1x/2 Weeks)
Anemia
Atezolizumab
Triple-Negative Breast Cancer
Fluorouracil
HIV Infections
Olesoxime
Muscular Atrophy, Spinal
Riluzole
Amyotrophic Lateral Sclerosis
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
bitopertin [RO4917838]
Schizophrenia
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Squamous Non-Small Cell Lung Cancer
Mycophenolate mofetil (MMF)
Lupus Nephritis
5-Fluorouracil
Gastric Cancer
cyclosporine A (CsA)
Heart Transplantation
Platinum chemotherapy (cisplatin or carboplatin)
Non-Squamous Non-Small Cell Lung Cancer
Pertuzumab IV
Early Breast Cancer
Venetoclax
Chronic Lymphocytic Leukemia
RO7234292 (RG6042)
Huntington Disease
Epirubicin
Breast Cancer
Regorafenib
Colorectal Cancer
trastuzumab [Herceptin]
Breast Cancer
Acitretin
HIV Infections
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Ranibizumab (10 mg/mL)
Neovascular Age-related Macular Degeneration
Nonbiologic DMARDs of investigator's choice
Rheumatoid Arthritis
Tocilizumab 162 mg
Rheumatoid Arthritis
Optional Endocrine Therapy of Investigator's Choice
Metastatic Breast Cancer
Epoetin alfa
Anemia
5-Fluorouracil (5-FU)
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Leucovorin calcium
Colorectal Cancer
Methotrexate
Rheumatoid Arthritis
Gemcitabine
Metastatic HER2-Positive Breast Cancer
Rituximab
Large B-Cell Lymphoma
Trastuzumab
Breast Cancer
Ribavirin
Hepatitis C, Chronic
erlotinib hydrochloride
Lung Cancer
Fulvestrant
Breast Cancer
Bevacizumab
Melanoma
R-pola-mini-CHP
DLBCL
Obinutuzumab
Large B-cell Lymphoma
Bendamustine
Follicular Lymphoma
Capecitabine
Biliary Tract Cancer
pegylated interferon alpha2a
Chronic Hepatitis C
Letrozole 2.5mg
Ovarian Neoplasm Epithelial
tenecteplase
Myocardial Infarction
background treatment
Tubular Breast Cancer Stage II
PEGIntron plus ribavirin
Chronic Hepatitis C Virus Infection
Trastuzumab in combination with pertuzumab
Haematological Malignancy
Pegylated Interferon/ribavirin
Chronic Hepatitis C
Peginterferon alpha-2a (Pegasys®)
HIV Infections
Folate
Rheumatoid Arthritis
Zilebesiran
High Risk Cardiovascular Disease
epoetin beta (NeoRecormon ®)
Kidney Failure
Invirase
Directly Observed Therapy
sirolimus versus mycophenolate mofetil
Diabetes Mellitus, Type 1
Obinutuzumab administration
Membranous Nephropathy - PLA2R Induced
Peginterferon alfa-2a + Ribavirin
Chronic Hepatitis c
XELOXA
Colorectal Cancer
LHRH Agonist
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
emtricitabine/tenofovir
HIV Infections
Irinotecan (CPT-11)
Colorectal Cancer
Ribavirin "loading" dose given
Hepatitis C
TRUVADA (EMTRICITABINE + TENOFOVIR DF)
Hepatitis B
Solanezumab
Alzheimers Disease
modified FOLFOX6 + bevacizumab
Metastatic Colorectal Cancer
Folinic Acid, interferon-alpha
Rectal Cancer
5 FU
Neoplasms
Intravitreal Ranibizumab 0.5 mg Injection
Diabetic Macular Edema
Treatment of physician's choice
Breast Cancer
Non-Biologic DMARDs
Rheumatoid Arthritis
rHuPH20
Non-Small Cell Lung Cancer
Tociluzumab
Relapsed or Refractory Follicular Lymphoma
Onartuzumab (MetMAb)
Gastric Cancer
Infliximab
Ulcerative Colitis
Vemurafenib
Melanoma
Ipatasertib
Triple-Negative Breast Cancer
Ranibizumab
Diabetic Macular Edema
Emicizumab
Hemophilia A
Afimkibart
Crohns Disease
tocilizumab [RoActemra/Actemra]
Rheumatoid Arthritis
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Anemia
Mircera
Anemia
erlotinib [Tarceva]
Non-Small Cell Lung Cancer
Saquinavir
HIV Infections
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
liposomal doxorubicin
Ovarian Cancer
Omalizumab
Nasal Polyps
csDMARDs
Rheumatoid Arthritis
pertuzumab [Perjeta]
Breast Cancer
tocilizumab
Rheumatoid Arthritis
bevacizumab [Avastin]
Non-Squamous Non-Small Cell Lung Cancer
ritonavir
HIV Infections
Etrolizumab
Crohn Disease
Epoetin beta
Anemia
Lurbinectedin
Small-Cell Lung Cancer
taspoglutide
Diabetes Mellitus Type 2
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-Negative Breast Cancer
Ibandronate
Post-Menopausal Osteoporosis
Entrectinib
Solid Tumors
peginterferon alfa-2a [Pegasys]
Hepatitis B, Chronic
Methoxy Polyethylene Glycol-Epoetin Beta
Anemia
mycophenolate mofetil (CellCept)
Myasthenia Gravis, Generalized
Onartuzumab
Glioblastoma
Dual Integrin Antagonist
Asthma
RO4917523 1.5 mg
Major Depressive Disorder
RO4995819
Major Depressive Disorder
Atezolizumab Cohort 7
Solid Tumors
boceprevir
Hepatitis C, Chronic
Abemaciclib
Ovarian Cancer
Bendamustine and subcutaneous rituximab
Aggressive Lymphoma
Levofolinic acid
Colorectal Cancer
Mesna
Lymphoma
Ro 24-7429
Sarcoma, Kaposi
mDCF
Anal Cancer
Doxorubicine
Untreated T-cell Angioimmunoblastic Lymphoma
Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Atopic Dermatitis
YL201
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
2-CdA
Lymphoma of Mucosa-Associated Lymphoid Tissue
Polyenylphosphatidylcholine (PPC)
Hepatitis C
antibody induction
Kidney Transplantation
Standard antipsychotic therapy
Schizophrenia
Second line chemotherapy
Breast Cancer
RO6864018
Hepatitis B, Chronic
RO5093151
Hypertension, Glaucoma, Open-Angle
Englumafusp alfa
Lymphoma, Non-Hodgkin
RO7268489
Progressive Multiple Sclerosis
ZN-A-1041
Advanced Solid Tumors
RO4588161
Hepatitis C, Chronic
Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
RO7046015
Parkinson's Disease
Aromatase Inhibitor
Breast Cancer
Diphenhydramine hydrochloride (HCl)
Lupus Nephritis
Hormonal Therapy
Breast Cancer
Mericitabine
Hepatitis C
Rituximab + CHOP chemotherapy
Primary Gastric Diffuse-Large B-Cell Lymphoma
Induction Chemotherapy
Breast Cancer
docetaxel, capecitabine
Metastatic Breast Cancer
PRM-151
Idiopathic Pulmonary Fibrosis
Tobemstomig
Urothelial Cancer
Obinutuzumab and Pixantrone
Lymphoma, Non-Hodgkin
Actos
Diabetes Mellitus Type 2
capecitabine (Xeloda)
Rectal Cancer
PHY906
Pancreatic Cancer
Erythropoietin Beta
Myelodysplastic Syndromes
DOX: Docetaxel, oxaliplatin, Capecitabine
Gastric Cancer
Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Gastroesophageal Junction Adenocarcinoma
Emicizumab Injection
Hemophilia A, Acquired
RO7490677
Primary Myelofibrosis
LABA
Asthma
RO5083945
Non-Squamous Non-Small Cell Lung Cancer
PEGPH20
Pancreatic Adenocarcinoma
RO5217790
Cervical Intraepithelial Neoplasia
RO4602522
Alzheimer's Disease
TRO40303
Acute Myocardial Infarctus
preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
Rectal Cancer
Zifibancimig
Macular Degeneration
Tarceva (OSI-774)
Colorectal Cancer
fotemustine
Glioblastoma Multiforme
Doxycline
Non-Small Cell Lung Cancer
capecitabine (Xeloda®)
Breast Cancer
obinutuzumab (RO5072759)
Non-Hodgkin's Lymphoma
Iberdomide
Multiple Myeloma
Standard platinum-based chemotherapy
Non-Small Cell Lung Cancer
bevacizumab (Avastin)
Liver Cancer
Metronidazole Actavis
Non-Squamous Non-Small Cell Lung Cancer
IMM-101
Colorectal Cancer
PTC-Pz
Breast Cancer
gemcitabine, oxaliplatin, capecitabine
Locally Advanced Pancreatic Cancer
ibandronate [Bondronat]
Pain; Bone Neoplasms; Neoplasm Metastasis
Mosunetuzumab (SC)
Follicular Lymphoma
RO4876904
Diabetes Mellitus Type 2
Crenezumab
Alzheimer Disease
setrobuvir
Hepatitis C, Chronic
Forimtamig
Relapsed or Refractory Multiple Myeloma
Induction- PF-06480605 50 mg SC Q4W
Moderate to Severe Ulcerative Colitis
Epidoxorubicin
Breast Cancer
ANA598
HCV Infection
Copegus
Hepatitis C, Chronic
N-acetylcysteine
Idiopathic Pulmonary Fibrosis
OpRegen
Age-Related Macular Degeneration
Pravastatin
Dyslipidemia
RG3421 120mg
Psoriasis
RO7795081
Obesity or Overweight
RO5027838
Diabetes Mellitus Type 2
Pertuzumab, trastuzumab
Esophageal Carcinoma
P38 Inhibitor (4) 150mg
Rheumatoid Arthritis
GDC-4198
Breast Cancer
Enicepatide
Overweight or Obese
Experimental
Diabetic Neuropathy
RG1662
Down Syndrome
Investigator's choice of anti-cancer treatment (except immunotherapy)
Breast Cancer
FOLFIRI + bevacizumab
Colorectal Cancer Metastatic
Basmisanil
Schizophrenia
Trastuzumab emtansine [Kadcyla]
Breast Cancer
Taxane (docetaxel or paclitaxel)
Breast Cancer
RO5190591
Hepatitis C, Chronic
Temozolomide (TMZ)
High Grade Glioma
Oxaliplatine
Metastatic Colorectal Cancer
RAR Gamma
Emphysema
RG7774
Diabetic Retinopathy
Obinutuzumab 25 MG/1 ML Intravenous Solution
Follicular Lymphoma
Samuraciclib
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Trastuzumab deruxtecan
HER2-positive Breast Cancer
Orlistat
Diabetes Mellitus
Perjeta Injectable Product
Breast Neoplasms
Fosamprenavir
HIV Infections
Ibrutinib / Bortezomib / Rituximab
Waldenstrom Macroglobulinemia
Olaparib+Bevacizumab to SCLC patients
Lung Cancer
Atezolizumab [TECENTRIQ]
Lymphoma
Ribociclib
Breast Cancer
NXT007
Hemophilia A
Ocrelizumab Test Formulation
Multiple Sclerosis
Xeloda
Breast Cancer
C.E.R.A.
Anemia
beta-lactam
Soft Tissue Infections
Mosunetuzumab (IV)
B-cell Non-Hodgkin Lymphoma
Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)
Colorectal Cancer
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Metastatic Breast Cancer
Tumor samples analysis
Triple Negative Breast Cancer
Rituxumab
B-cell Non-Hodgkin Lymphoma
Docetaxel, Cisplatin, 5-FU and Cetuximab
Nasopharyngeal Carcinoma
Didanosine
HIV Infections
Folinic Acid
Rectal Cancer
Polatuzumab vedotin (Liquid)
Lymphoma
Autogene Cevumeran
Muscle-invasive Urothelial Carcinoma
RO7247669 2100 mg
Melanoma
Epothilone D
Breast Cancer
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
HER2-Positive Early Breast Cancer
Interferon alfa-2a
Renal Cell Cancer
Atezolizumab plus Tiraglolumab
Squamous Cell Carcinoma of the Anal Canal
Interleukin 2
HIV Infections
GK Activator (2)
Diabetes Mellitus Type 2
Association atezolizumab + BDB001 + RT
Solid Tumor, Adult
Peg-interféron alpha 2a + ribavirin
Hepatitis
Axitinib
Renal Cell Carcinoma
Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.
Follicular Lymphoma
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab
Adenocarcinoma of the Gastroesophageal Junction
Atezolizumab (MPDL3280A) [TECENTRIQ]
Lymphoma, Follicular
Immunochemotherapy
Central Nervous System Lymphoma
Bevacizumab 15 mg/kg
Advanced Liver Cancers
Erlotinib + docetaxel
Non Small Cell Lung Cancer
DPP-IV Inhibitor
Diabetes Mellitus Type 2
TCS Cream
Atopic Dermatitis
SPK-8011QQ
Hemophilia A
PEGASYS [peginterferon alfa-2a]
Hepatitis B, Chronic
MSTT1041A
Asthma
RO7017773
Autism Spectrum Disorder (ASD)
RO 205-2349
Diabetes
Danoprevir
Hepatitis C, Chronic
Rituximab and DexaBEAM
Relapsed Non-Hodgkin-Lymphoma
RO5024048
Hepatitis C, Chronic
vismodegib
Basal Cell Carcinoma
RO7247669
Melanoma
enfuvirtide [Fuzeon]
HIV Infections
Tiragolumab and Atezolizumab IV FDC
PD-L1-selected Solid Tumors
RG7314
Autism Spectrum Disorder
Tociliuzumab
COVID-19 Pneumonia
Herceptin+XELOX
Metastatic or Recurrent Gastric Adenocarcinoma
Tocilizumab + Glucocorticoids (GCs)
Giant Cell Arteritis
Olesoxime (TRO19622)
Chemotherapy-Induced Peripheral Neuropathy
RO4998452
Diabetes Mellitus Type 2
Ribavirin [Copegus]
Hepatitis C, Chronic
Atezolizumab 1200 mg in 20 ML Injection
Extensive-stage Small Cell Lung Cancer
RO7126209
Alzheimers Disease
Tominersen
Huntington Disease
Carboplatin/Cisplatin
Nasopharyngeal Cancer
AT-527
COVID-19
Endocrine therapy
HER2-positive Breast Cancer
RO6889450
Schizophrenia, Schizoaffective Disorder
SGN-LIV1A
Metastatic Breast Cancer
FOLFOX induction regimen
Colorectal Cancer
Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Advanced Gastric Cancer
First line chemotherapy
Mantle Cell Lymphoma
fluorouracil (5FU)
Colorectal Cancer
Obinutuzumab Injection [Gazyva]
Stage II Grade 1 Follicular Lymphoma
Diprosone
Metastatic Colorectal Cancer
Atezolizumab 1200 mg/m2
Locally Advanced or Metastatic Urothelial Carcinoma
R-EPOCH and cART
Lymphoma, AIDS Related
RO4917523 0.5 mg
Fragile X Syndrome
Arm A: Atezolizumab and Radiotherapy
Penile Cancer
Mycophenolate Mofetil/Mycophenolic Acid
Lupus Nephritis
RO5313534
Alzheimer's Disease
Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Chronic Hepatitis B
RO5190591 (Danoprevir)
Hepatitis C, Chronic
Balovaptan
Stress Disorders, Post-Traumatic
Carboplatin-based chemotherapy
Non-Small Cell Lung Cancer
Pegylated Interferon (Peginterferon) Alfa-2a
Hepatitis B, Chronic
Glofitamab + Obinutuzumab
Richter Syndrome
Lomvastomig
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Tenofovir-Emtricitabine
Leukoencephalopathy, Progressive Multifocal
Standard taxane therapy
Breast Cancer
Tocilizumab 20 MG/ML
Sars-CoV2
GC33
Carcinoma, Hepatocellular
Gemcitabine+erlotinib
Metastatic Pancreatic Cancer
RO4905417
Coronary Heart Disease, Graft Occlusion, Vascular
Pertuzumab + trastuzumab
Elderly Metastatic Breast Cancer Population
pralsetinib (BLU-667)
RET-altered Non Small Cell Lung Cancer
SSRI
Obsessive-Compulsive Disorder
P38 Inhibitor (4)
Rheumatoid Arthritis
Ceftriaxone
Pneumonia, Bacterial
danoprevir + ritonavir
Hepatitis C, Chronic
eloxatin
Colorectal Cancer
PEG-IFN alfa-2a, Tenofovir
Hepatitis D
Bendamustine, Rituximab, Lenalidomide
Chronic Lymphocytic Leukemia
Nucleos(t)ide (NUC)
Hepatitis B, Chronic
Atezolizumab Injection [Tecentriq]
Bladder Cancer
MPDL3280A
Non-small Cell Lung Cancer
Peg-interferon alpha 2a (drug)
Hepatitis C, Chronic
Inhaled corticposteroids (ICS)
Asthma
rituximab (anti-CD20)
Sjogren's Syndrome
Ipatasertib 300mg
Metastatic Breast Cancer
Myocet
Breast Cancer
Optimized Background ARVs
HIV Infections
Abacavir sulfate
HIV Infections
bevacizumab and trabectedin
Ovarian Epithelial Cancer Recurrent
RO5459072
Sjogren's Syndrome
Alogabat
Angelman Syndrome
89Zr-Df-IAB22M2C
Non-Hodgkins Lymphoma
GA101
Chronic Lymphocytic Leucemia
RO5185426
Malignant Melanoma
Mosunetuzumab Intravenous (IV)
Diffuse Large B-cell Lymphoma
Ribavirine
Chronic Hepatitis C
RO4917523
Fragile X Syndrome
RO7269162
Alzheimer's Disease
Erlotinib, escalating dose
Pancreatic Cancer
L-Leucovorin
Metastatic Colorectal Cancer
Taspoglutide 20mg
Diabetes Mellitus Type 2
RO6958688
Carcinoma, Non-Small-Cell Lung
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Breast Neoplasms
RO4929097
Non-Squamous Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RO7239361 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
RO7204239 | Phase 3 | Obesity | - | - |
trastuzumab (Herceptin®) | Phase 3 | Breast Cancer | - | - |
mycophenolate mofetil [CellCept] | Phase 3 | Myasthenia Gravis Generalised | - | - |
Lenvatinib | Phase 3 | Unresectable Hepatocellular Carcinoma | - | - |
Eculizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Pirfenidone | Phase 3 | Lung Diseases, Interstitial | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Carcinoma, Non-Squamous Non-Small Cell Lung | - | - |
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) | Phase 3 | Early Breast Cancer | - | - |
Trastuzumab IV | Phase 3 | HER2-positive Early Breast Cancer | - | - |
Other Combination Anti-Cancer Therapies | Phase 3 | Solid Tumors | - | - |
Valganciclovir | Phase 3 | Cytomegalovirus Infections | - | - |
Filgrastim | Phase 3 | Triple-negative Breast Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 3 | Anemia | - | - |
Herceptin | Phase 3 | Breast Cancer | - | - |
Trastuzumab Emtansine | Phase 3 | Breast Cancer | - | - |
Fenebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Glofitamab | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
capecitabine [Xeloda] | Phase 3 | Colorectal Cancer | - | - |
Peginterferon alfa-2a | Phase 3 | Carcinoma, Hepatocellular | - | - |
Cladribine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Post-Menopausal Osteopenia | - | - |
Trontinemab | Phase 3 | Alzheimers Disease | - | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Alectnib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Inavolisib | Phase 3 | Breast Cancer | - | - |
Leucovorin (LV) | Phase 3 | Colorectal Cancer | - | - |
CHOP | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
rituximab [MabThera] | Phase 3 | Rheumatoid Arthritis | - | - |
RO4917838 | Phase 3 | Schizophrenia | - | - |
Baseline Treatment | Phase 3 | Neuromyelitis Optica (NMO) | - | - |
Acetaminophen/Paracetamol | Phase 3 | Systemic Lupus Erythematosus | - | - |
Phesgo | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - | - |
Fludarabine Phosphate | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
methoxy polyethylene glycol-epoetin beta [C.E.R.A.] | Phase 3 | Anemia | - | - |
Ortho-Novum® 1/35 | Phase 3 | Rheumatoid Arthritis | - | - |
PEGASYS | Phase 3 | Hepatitis C, Chronic | - | - |
RO7771950 | Phase 3 | HER2-positive Breast Cancer | - | - |
orlistat [Xenical] | Phase 3 | Obesity | - | - |
aleglitazar+metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
dalcetrapib | Phase 3 | Coronary Heart Disease | - | - |
Tiragolumab and Atezolizumab | Phase 3 | Cancer | - | - |
Cobimetinib | Phase 3 | Melanoma | - | - |
DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
MabThera/Rituxan | Phase 3 | Rheumatoid Arthritis | - | - |
RO7234292 | Phase 3 | Huntingtons Disease | - | - |
Onartuzumab [MetMAb] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
epoetin beta [NeoRecormon] | Phase 3 | Anemia | - | - |
Crovalimab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - | - |
Entecavir | Phase 3 | Pediatric Immuno-Tolerant Chronic Hepatitis B | - | - |
Mosunetuzumab | Phase 3 | Non-Hodgkin Lymphoma | - | - |
Prasinezumab | Phase 3 | Parkinsons Disease | - | - |
Dalcetrapib (RO4607381) | Phase 3 | Coronary Heart Disease | - | - |
FEC Chemotherapy | Phase 3 | Breast Cancer | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
Interferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Evidence-based medical care for Acute Coronary Syndrome | Phase 3 | Coronary Heart Disease | - | - |
Tiragolumab | Phase 3 | Small Cell Lung Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Phase 3 | Anemia | - | - |
methylprednisolone | Phase 3 | Rheumatoid Arthritis | - | - |
Vamikibart | Phase 3 | Diabetic Macular Edema | - | - |
Factor VIII (FVIII) | Phase 3 | Hemophilia A | - | - |
Pralsetinib | Phase 3 | RET-fusion Non Small Cell Lung Cancer | - | - |
Anti-VEGF Therapy | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
epoetin alfa or beta | Phase 3 | Anemia | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Remdesivir | Phase 3 | COVID-19 Pneumonia | - | - |
Polatuzumab Vedotin | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
r-HuEPO | Phase 3 | Anemia | - | - |
Fingolimod | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Sefaxersen (RO7434656) | Phase 3 | Primary IgA Nephropathy | - | - |
tocilizumab [RoActemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab (TCZ) | Phase 3 | Rheumatoid Arthritis | - | - |
Valganciclovir CMV Prophylaxis | Phase 3 | Cytomegalovirus Infections | - | - |
Neo-adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
Enfuvirtide | Phase 3 | HIV Infections | - | - |
Pertuzumab | Phase 3 | Breast Cancer | - | - |
Taxane-based chemotherapy | Phase 3 | Breast Cancer | - | - |
Cyclosporine | Phase 3 | Renal Transplantation | - | - |
23-PPV | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
FAP IL2V | Phase 3 | Cancer | - | - |
Alimta or Taxotere | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Oxaliplatin 130 mg/m^2 | Phase 3 | Colorectal Cancer | - | - |
Non-steroidal anti-inflammatory drugs (NSAIDs) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
5-Fluoruracil | Phase 3 | Gastric Cancer | - | - |
Giredestrant | Phase 3 | Endometrial Cancer | - | - |
Oseltamivir IV | Phase 3 | Influenza | - | - |
Interferon alfa 2a [Roferon] | Phase 3 | Renal Cell Cancer | - | - |
Disease-modifying anti-rheumatic drugs | Phase 3 | Rheumatoid Arthritis | - | - |
Becavizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Azathioprine | Phase 3 | Rheumatoid Arthritis | - | - |
Crizotinib | Phase 3 | Neoplasms | - | - |
Bitopertin | Phase 3 | Beta-Thalassemia | - | - |
Pegylated Interferon Alfa-2a | Phase 3 | Chronic Myelogenous Leukemia | - | - |
Divarasib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Rituximab SC | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
saquinavir [Invirase] | Phase 3 | HIV Infections | - | - |
Optimized background antiretroviral regimen (OB) | Phase 3 | HIV Infections | - | - |
Permitted DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
exenatide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Ocrelizumab IV | Phase 3 | Relapsing Multiple Sclerosis | - | - |
bitopertin [RO4917838] level 1 | Phase 3 | Schizophrenia | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
Antipsychotics | Phase 3 | Schizophrenia | - | - |
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg | Phase 3 | Hepatitis B, Chronic | - | - |
Prednisone/Prednisolone | Phase 3 | Metastatic Prostate Cancer | - | - |
Recombinant Hepatitis B Virus Vaccine | Phase 3 | Hepatitis B | - | - |
rFVIIa | Phase 3 | Hemophilia A | - | - |
Taxotere | Phase 3 | Breast Cancer | - | - |
Fluoropyrimidine-based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
CDK4/6i | Phase 3 | Breast Cancer | - | - |
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | Phase 3 | Diabetic Retinopathy | - | - |
CMF | Phase 3 | Breast Cancer | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Ganciclovir | Phase 3 | Cytomegalovirus Retinitis | - | - |
tocilizumab SC | Phase 3 | Rheumatoid Arthritis | - | - |
Lamivudine | Phase 3 | HIV Infections | - | - |
PDS Implant with Ranibizumab 100 mg/mL | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Erlotinib | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
satralizumab | Phase 3 | Neuromyelitis Optica Spectrum Disorder | - | - |
MMF | Phase 3 | Lupus Nephritis | - | - |
interferon-a-2a | Phase 3 | Lymphoma | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
TRO19622 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
XELOX | Phase 3 | Colorectal Cancer | - | - |
Standard adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
DMARD | Phase 3 | Rheumatoid Arthritis | - | - |
Mycophenolate Mofetil 2 g/Day | Phase 3 | Pemphigus Vulgaris (PV) | - | - |
Lebrikizumab | Phase 3 | Asthma | - | - |
Faricimab | Phase 3 | Wet Macular Degeneration | - | - |
Pegylated-interferon Alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Standard chemotherapy | Phase 3 | Breast Cancer | - | - |
von Willebrand Factor (VWF) Concentrates | Phase 3 | Von Willebrand Disease, Type 3 | - | - |
Oral Corticosteroids | Phase 3 | Rheumatoid Arthritis | - | - |
valganciclovir [Valcyte] | Phase 3 | Cytomegalovirus Infections | - | - |
bevacizumab, erlotinib | Phase 3 | Colorectal Cancer | - | - |
Acetaminophen/ Paracetamol | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | - | - |
Corticosteroids | Phase 3 | Breast Cancer | - | - |
Antihistamine | Phase 3 | Multiple Sclerosis | - | - |
epoetin | Phase 3 | Anemia | - | - |
Human Coagulation Factor VIII | Phase 3 | Hemophilia A | - | - |
fusidic acid [Verutex] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Rituximab IV | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
Risdiplam | Phase 3 | Muscular Atrophy, Spinal | - | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - | - |
Pegylated Interferon (PEG-IFN) alfa-2a | Phase 3 | Hepatitis D, Chronic | - | - |
oseltamivir | Phase 3 | Influenza, Human | - | - |
Gemcitabine (Chemotherapy) | Phase 3 | Ovarian Cancer | - | - |
Second-Line Chemotherapy | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Zalcitabine | Phase 3 | HIV Infections | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | - | - |
Cevostamab | Phase 3 | Multiple Myeloma | - | - |
Etrozulimab | Phase 3 | Ulcerative Colitis | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Neoral | Phase 3 | Kidney Transplantation | - | - |
Gantenerumab | Phase 3 | Alzheimer's Disease | - | - |
PDS Implant filled with 100 mg/mL Ranibizumab | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
anti-IL-2R | Phase 3 | Kidney Transplantation | - | - |
Endocrine Therapy of Physician's Choice | Phase 3 | Early Breast Cancer | - | - |
Delavirdine mesylate | Phase 3 | HIV Infections | - | - |
adefovir dipivoxil | Phase 3 | Hepatitis B, Chronic | - | - |
Chemotherapy (Induction Period) | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
tenofovir | Phase 3 | Hepatitis D, Chronic | - | - |
RO0503821 (1x/2 Weeks) | Phase 3 | Anemia | - | - |
Atezolizumab | Phase 3 | Triple-Negative Breast Cancer | - | - |
Fluorouracil | Phase 3 | HIV Infections | - | - |
Olesoxime | Phase 3 | Muscular Atrophy, Spinal | - | - |
Riluzole | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
bitopertin [RO4917838] | Phase 3 | Schizophrenia | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody | Phase 3 | Squamous Non-Small Cell Lung Cancer | - | - |
Mycophenolate mofetil (MMF) | Phase 3 | Lupus Nephritis | - | - |
5-Fluorouracil | Phase 3 | Gastric Cancer | - | - |
cyclosporine A (CsA) | Phase 3 | Heart Transplantation | - | - |
Platinum chemotherapy (cisplatin or carboplatin) | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Pertuzumab IV | Phase 3 | Early Breast Cancer | - | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
RO7234292 (RG6042) | Phase 3 | Huntington Disease | - | - |
Epirubicin | Phase 3 | Breast Cancer | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
trastuzumab [Herceptin] | Phase 3 | Breast Cancer | - | - |
Acitretin | Phase 3 | HIV Infections | - | - |
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) | Phase 3 | Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | - | - |
Ranibizumab (10 mg/mL) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Nonbiologic DMARDs of investigator's choice | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab 162 mg | Phase 3 | Rheumatoid Arthritis | - | - |
Optional Endocrine Therapy of Investigator's Choice | Phase 3 | Metastatic Breast Cancer | - | - |
Epoetin alfa | Phase 3 | Anemia | - | - |
5-Fluorouracil (5-FU) | Phase 3 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | - | - |
Leucovorin calcium | Phase 3 | Colorectal Cancer | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Gemcitabine | Phase 3 | Metastatic HER2-Positive Breast Cancer | - | - |
Rituximab | Phase 3 | Large B-Cell Lymphoma | - | - |
Trastuzumab | Phase 3 | Breast Cancer | - | - |
Ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
erlotinib hydrochloride | Phase 3 | Lung Cancer | - | - |
Fulvestrant | Phase 3 | Breast Cancer | - | - |
Bevacizumab | Phase 3 | Melanoma | - | - |
R-pola-mini-CHP | Phase 3 | DLBCL | - | - |
Obinutuzumab | Phase 3 | Large B-cell Lymphoma | - | - |
Bendamustine | Phase 3 | Follicular Lymphoma | - | - |
Capecitabine | Phase 3 | Biliary Tract Cancer | - | - |
pegylated interferon alpha2a | Phase 3 | Chronic Hepatitis C | - | - |
Letrozole 2.5mg | Phase 3 | Ovarian Neoplasm Epithelial | - | - |
tenecteplase | Phase 3 | Myocardial Infarction | - | - |
background treatment | Phase 3 | Tubular Breast Cancer Stage II | - | - |
PEGIntron plus ribavirin | Phase 3 | Chronic Hepatitis C Virus Infection | - | - |
Trastuzumab in combination with pertuzumab | Phase 3 | Haematological Malignancy | - | - |
Pegylated Interferon/ribavirin | Phase 3 | Chronic Hepatitis C | - | - |
Peginterferon alpha-2a (Pegasys®) | Phase 3 | HIV Infections | - | - |
Folate | Phase 3 | Rheumatoid Arthritis | - | - |
Zilebesiran | Phase 3 | High Risk Cardiovascular Disease | - | - |
epoetin beta (NeoRecormon ®) | Phase 3 | Kidney Failure | - | - |
Invirase | Phase 3 | Directly Observed Therapy | - | - |
sirolimus versus mycophenolate mofetil | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Obinutuzumab administration | Phase 3 | Membranous Nephropathy - PLA2R Induced | - | - |
Peginterferon alfa-2a + Ribavirin | Phase 3 | Chronic Hepatitis c | - | - |
XELOXA | Phase 3 | Colorectal Cancer | - | - |
LHRH Agonist | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | - | - |
emtricitabine/tenofovir | Phase 3 | HIV Infections | - | - |
Irinotecan (CPT-11) | Phase 3 | Colorectal Cancer | - | - |
Ribavirin "loading" dose given | Phase 3 | Hepatitis C | - | - |
TRUVADA (EMTRICITABINE + TENOFOVIR DF) | Phase 3 | Hepatitis B | - | - |
Solanezumab | Phase 3 | Alzheimers Disease | - | - |
modified FOLFOX6 + bevacizumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Folinic Acid, interferon-alpha | Phase 3 | Rectal Cancer | - | - |
5 FU | Phase 3 | Neoplasms | - | - |
Intravitreal Ranibizumab 0.5 mg Injection | Phase 3 | Diabetic Macular Edema | - | - |
Treatment of physician's choice | Phase 3 | Breast Cancer | - | - |
Non-Biologic DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
rHuPH20 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tociluzumab | Phase 3 | Relapsed or Refractory Follicular Lymphoma | - | - |
Onartuzumab (MetMAb) | Phase 3 | Gastric Cancer | - | - |
Infliximab | Phase 3 | Ulcerative Colitis | - | - |
Vemurafenib | Phase 3 | Melanoma | - | - |
Ipatasertib | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ranibizumab | Phase 3 | Diabetic Macular Edema | - | - |
Emicizumab | Phase 3 | Hemophilia A | - | - |
Afimkibart | Phase 3 | Crohns Disease | - | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.) | Phase 3 | Anemia | - | - |
Mircera | Phase 3 | Anemia | - | - |
erlotinib [Tarceva] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Saquinavir | Phase 3 | HIV Infections | - | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - | - |
liposomal doxorubicin | Phase 3 | Ovarian Cancer | - | - |
Omalizumab | Phase 3 | Nasal Polyps | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
pertuzumab [Perjeta] | Phase 3 | Breast Cancer | - | - |
tocilizumab | Phase 3 | Rheumatoid Arthritis | - | - |
bevacizumab [Avastin] | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
ritonavir | Phase 3 | HIV Infections | - | - |
Etrolizumab | Phase 3 | Crohn Disease | - | - |
Epoetin beta | Phase 3 | Anemia | - | - |
Lurbinectedin | Phase 3 | Small-Cell Lung Cancer | - | - |
taspoglutide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ibandronate | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Entrectinib | Phase 3 | Solid Tumors | - | - |
peginterferon alfa-2a [Pegasys] | Phase 3 | Hepatitis B, Chronic | - | - |
Methoxy Polyethylene Glycol-Epoetin Beta | Phase 3 | Anemia | - | - |
mycophenolate mofetil (CellCept) | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Onartuzumab | Phase 3 | Glioblastoma | - | - |
Dual Integrin Antagonist | Phase 2 | Asthma | - | - |
RO4917523 1.5 mg | Phase 2 | Major Depressive Disorder | - | - |
RO4995819 | Phase 2 | Major Depressive Disorder | - | - |
Atezolizumab Cohort 7 | Phase 2 | Solid Tumors | - | - |
boceprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Abemaciclib | Phase 2 | Ovarian Cancer | - | - |
Bendamustine and subcutaneous rituximab | Phase 2 | Aggressive Lymphoma | - | - |
Levofolinic acid | Phase 2 | Colorectal Cancer | - | - |
Mesna | Phase 2 | Lymphoma | - | - |
Ro 24-7429 | Phase 2 | Sarcoma, Kaposi | - | - |
mDCF | Phase 2 | Anal Cancer | - | - |
Doxorubicine | Phase 2 | Untreated T-cell Angioimmunoblastic Lymphoma | - | - |
Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%) | Phase 2 | Atopic Dermatitis | - | - |
YL201 | Phase 2 | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | - | - |
2-CdA | Phase 2 | Lymphoma of Mucosa-Associated Lymphoid Tissue | - | - |
Polyenylphosphatidylcholine (PPC) | Phase 2 | Hepatitis C | - | - |
antibody induction | Phase 2 | Kidney Transplantation | - | - |
Standard antipsychotic therapy | Phase 2 | Schizophrenia | - | - |
Second line chemotherapy | Phase 2 | Breast Cancer | - | - |
RO6864018 | Phase 2 | Hepatitis B, Chronic | - | - |
RO5093151 | Phase 2 | Hypertension, Glaucoma, Open-Angle | - | - |
Englumafusp alfa | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
RO7268489 | Phase 2 | Progressive Multiple Sclerosis | - | - |
ZN-A-1041 | Phase 2 | Advanced Solid Tumors | - | - |
RO4588161 | Phase 2 | Hepatitis C, Chronic | - | - |
Fulvestrant or an Aromatase Inhibitor (Physician Choice) | Phase 2 | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | - | - |
RO7046015 | Phase 2 | Parkinson's Disease | - | - |
Aromatase Inhibitor | Phase 2 | Breast Cancer | - | - |
Diphenhydramine hydrochloride (HCl) | Phase 2 | Lupus Nephritis | - | - |
Hormonal Therapy | Phase 2 | Breast Cancer | - | - |
Mericitabine | Phase 2 | Hepatitis C | - | - |
Rituximab + CHOP chemotherapy | Phase 2 | Primary Gastric Diffuse-Large B-Cell Lymphoma | - | - |
Induction Chemotherapy | Phase 2 | Breast Cancer | - | - |
docetaxel, capecitabine | Phase 2 | Metastatic Breast Cancer | - | - |
PRM-151 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Tobemstomig | Phase 2 | Urothelial Cancer | - | - |
Obinutuzumab and Pixantrone | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - | - |
capecitabine (Xeloda) | Phase 2 | Rectal Cancer | - | - |
PHY906 | Phase 2 | Pancreatic Cancer | - | - |
Erythropoietin Beta | Phase 2 | Myelodysplastic Syndromes | - | - |
DOX: Docetaxel, oxaliplatin, Capecitabine | Phase 2 | Gastric Cancer | - | - |
Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Phase 2 | Gastroesophageal Junction Adenocarcinoma | - | - |
Emicizumab Injection | Phase 2 | Hemophilia A, Acquired | - | - |
RO7490677 | Phase 2 | Primary Myelofibrosis | - | - |
LABA | Phase 2 | Asthma | - | - |
RO5083945 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
PEGPH20 | Phase 2 | Pancreatic Adenocarcinoma | - | - |
RO5217790 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
RO4602522 | Phase 2 | Alzheimer's Disease | - | - |
TRO40303 | Phase 2 | Acute Myocardial Infarctus | - | - |
preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine | Phase 2 | Rectal Cancer | - | - |
Zifibancimig | Phase 2 | Macular Degeneration | - | - |
Tarceva (OSI-774) | Phase 2 | Colorectal Cancer | - | - |
fotemustine | Phase 2 | Glioblastoma Multiforme | - | - |
Doxycline | Phase 2 | Non-Small Cell Lung Cancer | - | - |
capecitabine (Xeloda®) | Phase 2 | Breast Cancer | - | - |
obinutuzumab (RO5072759) | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Iberdomide | Phase 2 | Multiple Myeloma | - | - |
Standard platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
bevacizumab (Avastin) | Phase 2 | Liver Cancer | - | - |
Metronidazole Actavis | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
IMM-101 | Phase 2 | Colorectal Cancer | - | - |
PTC-Pz | Phase 2 | Breast Cancer | - | - |
gemcitabine, oxaliplatin, capecitabine | Phase 2 | Locally Advanced Pancreatic Cancer | - | - |
ibandronate [Bondronat] | Phase 2 | Pain; Bone Neoplasms; Neoplasm Metastasis | - | - |
Mosunetuzumab (SC) | Phase 2 | Follicular Lymphoma | - | - |
RO4876904 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Crenezumab | Phase 2 | Alzheimer Disease | - | - |
setrobuvir | Phase 2 | Hepatitis C, Chronic | - | - |
Forimtamig | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Induction- PF-06480605 50 mg SC Q4W | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Epidoxorubicin | Phase 2 | Breast Cancer | - | - |
ANA598 | Phase 2 | HCV Infection | - | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - | - |
N-acetylcysteine | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
OpRegen | Phase 2 | Age-Related Macular Degeneration | - | - |
Pravastatin | Phase 2 | Dyslipidemia | - | - |
RG3421 120mg | Phase 2 | Psoriasis | - | - |
RO7795081 | Phase 2 | Obesity or Overweight | - | - |
RO5027838 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Pertuzumab, trastuzumab | Phase 2 | Esophageal Carcinoma | - | - |
P38 Inhibitor (4) 150mg | Phase 2 | Rheumatoid Arthritis | - | - |
GDC-4198 | Phase 2 | Breast Cancer | - | - |
Enicepatide | Phase 2 | Overweight or Obese | - | - |
Experimental | Phase 2 | Diabetic Neuropathy | - | - |
RG1662 | Phase 2 | Down Syndrome | - | - |
Investigator's choice of anti-cancer treatment (except immunotherapy) | Phase 2 | Breast Cancer | - | - |
FOLFIRI + bevacizumab | Phase 2 | Colorectal Cancer Metastatic | - | - |
Basmisanil | Phase 2 | Schizophrenia | - | - |
Trastuzumab emtansine [Kadcyla] | Phase 2 | Breast Cancer | - | - |
Taxane (docetaxel or paclitaxel) | Phase 2 | Breast Cancer | - | - |
RO5190591 | Phase 2 | Hepatitis C, Chronic | - | - |
Temozolomide (TMZ) | Phase 2 | High Grade Glioma | - | - |
Oxaliplatine | Phase 2 | Metastatic Colorectal Cancer | - | - |
RAR Gamma | Phase 2 | Emphysema | - | - |
RG7774 | Phase 2 | Diabetic Retinopathy | - | - |
Obinutuzumab 25 MG/1 ML Intravenous Solution | Phase 2 | Follicular Lymphoma | - | - |
Samuraciclib | Phase 2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | - | - |
Trastuzumab deruxtecan | Phase 2 | HER2-positive Breast Cancer | - | - |
Orlistat | Phase 2 | Diabetes Mellitus | - | - |
Perjeta Injectable Product | Phase 2 | Breast Neoplasms | - | - |
Fosamprenavir | Phase 2 | HIV Infections | - | - |
Ibrutinib / Bortezomib / Rituximab | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Olaparib+Bevacizumab to SCLC patients | Phase 2 | Lung Cancer | - | - |
Atezolizumab [TECENTRIQ] | Phase 2 | Lymphoma | - | - |
Ribociclib | Phase 2 | Breast Cancer | - | - |
NXT007 | Phase 2 | Hemophilia A | - | - |
Ocrelizumab Test Formulation | Phase 2 | Multiple Sclerosis | - | - |
Xeloda | Phase 2 | Breast Cancer | - | - |
C.E.R.A. | Phase 2 | Anemia | - | - |
beta-lactam | Phase 2 | Soft Tissue Infections | - | - |
Mosunetuzumab (IV) | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) | Phase 2 | Colorectal Cancer | - | - |
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg | Phase 2 | Metastatic Breast Cancer | - | - |
Tumor samples analysis | Phase 2 | Triple Negative Breast Cancer | - | - |
Rituxumab | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
Docetaxel, Cisplatin, 5-FU and Cetuximab | Phase 2 | Nasopharyngeal Carcinoma | - | - |
Didanosine | Phase 2 | HIV Infections | - | - |
Folinic Acid | Phase 2 | Rectal Cancer | - | - |
Polatuzumab vedotin (Liquid) | Phase 2 | Lymphoma | - | - |
Autogene Cevumeran | Phase 2 | Muscle-invasive Urothelial Carcinoma | - | - |
RO7247669 2100 mg | Phase 2 | Melanoma | - | - |
Epothilone D | Phase 2 | Breast Cancer | - | - |
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC) | Phase 2 | HER2-Positive Early Breast Cancer | - | - |
Interferon alfa-2a | Phase 2 | Renal Cell Cancer | - | - |
Atezolizumab plus Tiraglolumab | Phase 2 | Squamous Cell Carcinoma of the Anal Canal | - | - |
Interleukin 2 | Phase 2 | HIV Infections | - | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Association atezolizumab + BDB001 + RT | Phase 2 | Solid Tumor, Adult | - | - |
Peg-interféron alpha 2a + ribavirin | Phase 2 | Hepatitis | - | - |
Axitinib | Phase 2 | Renal Cell Carcinoma | - | - |
Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. | Phase 2 | Follicular Lymphoma | - | - |
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab | Phase 2 | Adenocarcinoma of the Gastroesophageal Junction | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ] | Phase 2 | Lymphoma, Follicular | - | - |
Immunochemotherapy | Phase 2 | Central Nervous System Lymphoma | - | - |
Bevacizumab 15 mg/kg | Phase 2 | Advanced Liver Cancers | - | - |
Erlotinib + docetaxel | Phase 2 | Non Small Cell Lung Cancer | - | - |
DPP-IV Inhibitor | Phase 2 | Diabetes Mellitus Type 2 | - | - |
TCS Cream | Phase 2 | Atopic Dermatitis | - | - |
SPK-8011QQ | Phase 2 | Hemophilia A | - | - |
PEGASYS [peginterferon alfa-2a] | Phase 2 | Hepatitis B, Chronic | - | - |
MSTT1041A | Phase 2 | Asthma | - | - |
RO7017773 | Phase 2 | Autism Spectrum Disorder (ASD) | - | - |
RO 205-2349 | Phase 2 | Diabetes | - | - |
Danoprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Rituximab and DexaBEAM | Phase 2 | Relapsed Non-Hodgkin-Lymphoma | - | - |
RO5024048 | Phase 2 | Hepatitis C, Chronic | - | - |
vismodegib | Phase 2 | Basal Cell Carcinoma | - | - |
RO7247669 | Phase 2 | Melanoma | - | - |
enfuvirtide [Fuzeon] | Phase 2 | HIV Infections | - | - |
Tiragolumab and Atezolizumab IV FDC | Phase 2 | PD-L1-selected Solid Tumors | - | - |
RG7314 | Phase 2 | Autism Spectrum Disorder | - | - |
Tociliuzumab | Phase 2 | COVID-19 Pneumonia | - | - |
Herceptin+XELOX | Phase 2 | Metastatic or Recurrent Gastric Adenocarcinoma | - | - |
Tocilizumab + Glucocorticoids (GCs) | Phase 2 | Giant Cell Arteritis | - | - |
Olesoxime (TRO19622) | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | - | - |
RO4998452 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Ribavirin [Copegus] | Phase 2 | Hepatitis C, Chronic | - | - |
Atezolizumab 1200 mg in 20 ML Injection | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
RO7126209 | Phase 2 | Alzheimers Disease | - | - |
Tominersen | Phase 2 | Huntington Disease | - | - |
Carboplatin/Cisplatin | Phase 2 | Nasopharyngeal Cancer | - | - |
AT-527 | Phase 2 | COVID-19 | - | - |
Endocrine therapy | Phase 2 | HER2-positive Breast Cancer | - | - |
RO6889450 | Phase 2 | Schizophrenia, Schizoaffective Disorder | - | - |
SGN-LIV1A | Phase 2 | Metastatic Breast Cancer | - | - |
FOLFOX induction regimen | Phase 2 | Colorectal Cancer | - | - |
Docetaxel, Capecitabine, Cisplatin, Bevacizumab | Phase 2 | Advanced Gastric Cancer | - | - |
First line chemotherapy | Phase 2 | Mantle Cell Lymphoma | - | - |
fluorouracil (5FU) | Phase 2 | Colorectal Cancer | - | - |
Obinutuzumab Injection [Gazyva] | Phase 2 | Stage II Grade 1 Follicular Lymphoma | - | - |
Diprosone | Phase 2 | Metastatic Colorectal Cancer | - | - |
Atezolizumab 1200 mg/m2 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | - | - |
R-EPOCH and cART | Phase 2 | Lymphoma, AIDS Related | - | - |
RO4917523 0.5 mg | Phase 2 | Fragile X Syndrome | - | - |
Arm A: Atezolizumab and Radiotherapy | Phase 2 | Penile Cancer | - | - |
Mycophenolate Mofetil/Mycophenolic Acid | Phase 2 | Lupus Nephritis | - | - |
RO5313534 | Phase 2 | Alzheimer's Disease | - | - |
Pegylated interferon alfa-2a plus nucleos(t)ide(s) | Phase 2 | Chronic Hepatitis B | - | - |
RO5190591 (Danoprevir) | Phase 2 | Hepatitis C, Chronic | - | - |
Balovaptan | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
Carboplatin-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Pegylated Interferon (Peginterferon) Alfa-2a | Phase 2 | Hepatitis B, Chronic | - | - |
Glofitamab + Obinutuzumab | Phase 2 | Richter Syndrome | - | - |
Lomvastomig | Phase 2 | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | - | - |
Tenofovir-Emtricitabine | Phase 2 | Leukoencephalopathy, Progressive Multifocal | - | - |
Standard taxane therapy | Phase 2 | Breast Cancer | - | - |
Tocilizumab 20 MG/ML | Phase 2 | Sars-CoV2 | - | - |
GC33 | Phase 2 | Carcinoma, Hepatocellular | - | - |
Gemcitabine+erlotinib | Phase 2 | Metastatic Pancreatic Cancer | - | - |
RO4905417 | Phase 2 | Coronary Heart Disease, Graft Occlusion, Vascular | - | - |
Pertuzumab + trastuzumab | Phase 2 | Elderly Metastatic Breast Cancer Population | - | - |
pralsetinib (BLU-667) | Phase 2 | RET-altered Non Small Cell Lung Cancer | - | - |
SSRI | Phase 2 | Obsessive-Compulsive Disorder | - | - |
P38 Inhibitor (4) | Phase 2 | Rheumatoid Arthritis | - | - |
Ceftriaxone | Phase 2 | Pneumonia, Bacterial | - | - |
danoprevir + ritonavir | Phase 2 | Hepatitis C, Chronic | - | - |
eloxatin | Phase 2 | Colorectal Cancer | - | - |
PEG-IFN alfa-2a, Tenofovir | Phase 2 | Hepatitis D | - | - |
Bendamustine, Rituximab, Lenalidomide | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Nucleos(t)ide (NUC) | Phase 2 | Hepatitis B, Chronic | - | - |
Atezolizumab Injection [Tecentriq] | Phase 2 | Bladder Cancer | - | - |
MPDL3280A | Phase 2 | Non-small Cell Lung Cancer | - | - |
Peg-interferon alpha 2a (drug) | Phase 2 | Hepatitis C, Chronic | - | - |
Inhaled corticposteroids (ICS) | Phase 2 | Asthma | - | - |
rituximab (anti-CD20) | Phase 2 | Sjogren's Syndrome | - | - |
Ipatasertib 300mg | Phase 2 | Metastatic Breast Cancer | - | - |
Myocet | Phase 2 | Breast Cancer | - | - |
Optimized Background ARVs | Phase 2 | HIV Infections | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
bevacizumab and trabectedin | Phase 2 | Ovarian Epithelial Cancer Recurrent | - | - |
RO5459072 | Phase 2 | Sjogren's Syndrome | - | - |
Alogabat | Phase 2 | Angelman Syndrome | - | - |
89Zr-Df-IAB22M2C | Phase 2 | Non-Hodgkins Lymphoma | - | - |
GA101 | Phase 2 | Chronic Lymphocytic Leucemia | - | - |
RO5185426 | Phase 2 | Malignant Melanoma | - | - |
Mosunetuzumab Intravenous (IV) | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
Ribavirine | Phase 2 | Chronic Hepatitis C | - | - |
RO4917523 | Phase 2 | Fragile X Syndrome | - | - |
RO7269162 | Phase 2 | Alzheimer's Disease | - | - |
Erlotinib, escalating dose | Phase 2 | Pancreatic Cancer | - | - |
L-Leucovorin | Phase 2 | Metastatic Colorectal Cancer | - | - |
Taspoglutide 20mg | Phase 2 | Diabetes Mellitus Type 2 | - | - |
RO6958688 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody | Phase 2 | Breast Neoplasms | - | - |
RO4929097 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Alzheimer's disease
3 drugs in this indication
Huntington's disease
2 drugs in this indication
oncology
2 drugs in this indication
neovascular age-related macular degeneration (nAMD)
2 drugs in this indication
Tuberculosis infection (latent TB) identification
1 drug in this indication
Breast Cancer
1 drug in this indication
dMMR/MSI-H metastatic colorectal cancer
1 drug in this indication
Unresectable Hepatocellular Carcinoma
1 drug in this indication
Paroxysmal Nocturnal Hemoglobinuria
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
muscle-invasive bladder cancer
1 drug in this indication
cyclospora detection
1 drug in this indication
Hepatitis D detection
1 drug in this indication
lupus
1 drug in this indication
Duchenne Muscular Dystrophy
1 drug in this indication
ADC-resistant cancers
1 drug in this indication
Bacterial vaginosis and Candida vaginitis diagnosis
1 drug in this indication
polypoidal choroidal vasculopathy (PCV), a sub-type of neovascular age-related macular degeneration (nAMD)
1 drug in this indication
Obesity
1 drug in this indication
lung cancer
1 drug in this indication
HER2-positive breast cancer
1 drug in this indication
Myasthenia Gravis Generalised
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Roche Holding AG's drug pipeline?→
CatalystAlert tracks 497 drug candidates in Roche Holding AG's (RHHBY) pipeline across Phase 3, Phase 2. Its lead program is RO7239361 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Roche Holding AG's next FDA catalyst?→
Roche Holding AG's (RHHBY) next tracked catalyst is a Phase 2 expected August 26, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RHHBY biotech catalysts?→
Add RHHBY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Roche Holding AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.